Clinical Trials Browser

Completed × Hereditary leiomyomatosis and renal cell cancer × Bevacizumab × Clear all

NCT01130519 2025-02-21

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Phase 2 Completed

83 enrolled 17 charts

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms